0
0

Chapter 53. Borderline Personality Disorder

John G. Gunderson, M.D.; Paul S. Links, M.D., F.R.C.P.C.
DOI: 10.1176/appi.books.9781585622986.263236

Sections

Excerpt

Our understanding and treatment of borderline personality disorder (BPD) continue to evolve. These patients were originally conceptualized as having a particular type of intrapsychic organization. The prospect of being able to understand the internal organization of such patients helped encourage the enormous rise in therapeutic enthusiasm for long-term, intensive, psychoanalytically informed treatments for these patients. The construct was modified when it was redefined as a syndrome with reliably identifiable and discriminating criteria (see Table 53–1 for the DSM-IV-TR criteria). After the adoption of BPD in DSM-III (American Psychiatric Association 1980), the disorder became the subject of empirical study. The research showed that borderline patients frequently recover from the disorder and that such recovery usually involves multiple forms and episodes of treatment. Investigators repeatedly found that borderline patients have significant deficits in their ability to tolerate affects, impulses, and aloneness. From these observations, as well as more general changes in mental health services, the treatment approach of the earlier era, in which long-term intensive psychoanalytic therapies were considered necessary, has been greatly modified.

Your session has timed out. Please sign back in to continue.
Sign In Your Session has timed out. Please sign back in to continue.
Sign In to Access Full Content
 
Username
Password
Sign in via Athens (What is this?)
Athens is a service for single sign-on which enables access to all of an institution's subscriptions on- or off-site.
Not a subscriber?

Subscribe Now/Learn More

PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing PsychiatryOnline@psych.org or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Table Reference Number
Table 53–1. DSM-IV-TR diagnostic criteria for borderline personality disorder
Table Reference Number
Table 53–2. Medication efficacy in areas of dyscontrol

References

Abend SM, Porder MS, Willick MS: Borderline Patients: Psychoanalytic Perspectives. New York, International Universities Press, 1983
 
Adityanjee MD, Schulz SC: Clinical use of quetiapine in disease states other than schizophrenia. J Clin Psychiatry 63 (suppl):32–38, 2002
 
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 3rd Edition. Washington, DC, American Psychiatric Association, 1980
 
American Psychiatric Association: Practice guideline for the treatment of patients with borderline personality disorder. Am J Psychiatry 158 (suppl):1–52, 2001
 
Bateman A, Fonagy P: The effectiveness of partial hospital in the treatment of borderline personality disorder: a randomized controlled trial. Am J Psychiatry 156:1563–1569, 1999
[PubMed]
 
Bateman AW, Fonagy P: Mentalization-based treatment of BPD. J Personal Disord 18:36–51, 2004
[PubMed]
 
Beck AT, Freeman A: Dependent personality disorder, in Cognitive Therapy of Personality Disorders. New York, Guilford, 1990, pp 283–308
 
Bender DS, Dolan RT, Skodol AE, et al: Treatment utilization by patients with personality disorders. Am J Psychiatry 158:295–302, 2001
[PubMed]
 
Bender DS, Skodol AE, Pagano ME, et al: Prospective assessment of treatment use by patients with personality disorders. Psychiatr Serv 57:254–257, 2006
[PubMed]
 
Benedetti F, Sforzini L, Colombo C, et al: Low-dose clozapine in acute and continuation treatment of severe borderline personality disorder. J Clin Psychiatry 59:103–107, 1998
[PubMed]
 
Blum N, Pfohl B, John DS, et al: STEPPS: a cognitive-behavioral systems-based group treatment for outpatients with borderline personality disorder—a preliminary report. Compr Psychiatry 43:301–310, 2002
[PubMed]
 
Bogenschutz MP, Nurnberg HG: Olanzapine versus placebo in the treatment of borderline personality disorder. J Clin Psychiatry 65:104–109, 2004
[PubMed]
 
Budman SH, Demby A, Soldz S, et al: Time-limited group psychotherapy for patients with personality disorders: outcome and dropouts. Int J Group Psychother 43:357–377, 1996
 
Buie DH, Adler G: The definitive treatment of the borderline personality. Int J Psychoanal Psychother 9:51–87, 1982–1983
[PubMed]
 
Chengappa KN, Baker RW, Sirri C: The successful use of clozapine in ameliorating severe self-mutilation in a patient with borderline personality disorder. J Personal Disord 9:76–82, 1995
 
Chengappa KN, Ebeling T, Kang JS, et al: Clozapine reduces severe self-mutilation and aggression in psychotic patients with borderline personality disorder. J Clin Psychiatry 60:477–484, 1999
[PubMed]
 
Chessick RD: Intensive psychotherapy of a borderline patient. Arch Gen Psychiatry 39:413–419, 1982
[PubMed]
 
Chiesa M, Fonagy P, Holmes J, et al: Residential versus community treatment of personality disorders: a comparative study of three treatment programs. Am J Psychiatry 161:1463–1470, 2004
[PubMed]
 
Clarkin JF, Yeomans FE, Kernberg OF: Psychotherapy for Borderline Personality. New York, Wiley, 1999
 
Clarkin JF, Levy KN, Lenzenweger MF, et al: The Personality Disorders Institute/Borderline Personality Research Foundation randomized control trial for borderline personality disorder: rationale, methods, and patient characteristics. J Personal Disord 18:52–72, 2004
[PubMed]
 
Coccaro EF, Kavoussi RJ: Fluoxetine and impulsive aggressive behavior in personality-disordered subjects. Arch Gen Psychiatry 54:1081–1088, 1997
[PubMed]
 
Cowdry RW, Gardner DL: Pharmacotherapy of borderline personality disorder: alprazolam, carbamazepine, trifluoperazine, and tranylcypromine. Arch Gen Psychiatry 45:111–119, 1988
[PubMed]
 
Dawson D, MacMillan H: Relationship Management of the Borderline Patient: From Understanding to Treatment. New York, Brunner/Mazel, 1993
 
De La Fuenta JM, Lotstra F: A trial of carbamazepine in borderline personality disorder. Eur Neuropsychopharmacol 4:479–486, 1994
 
Feske U, Mulsant BH, Pilkonis PA, et al: Clinical outcome of ECT in patients with major depression and comorbid borderline personality disorder. Am J Psychiatry 161:2073–2080, 2004
[PubMed]
 
Frankenburg FR, Zanarini MC: Clozapine treatment of borderline patients: a preliminary study. Compr Psychiatry 34:402–405, 1993
[PubMed]
 
Fruzzetti AE, Boulanger J: Family involvement in treatment of borderline personality disorder, in Borderline Personality Disorder Perspectives: From Professional to Family Member. Edited by Gunderson JG, Hoffman PD. Washington, DC, American Psychiatric Publishing, 2005, pp 151–164
 
Gabbard GO: Splitting in hospital treatment. Am J Psychiatry 146:444–451, 1989
[PubMed]
 
Gabbard GO, Willkinson SM: Management of Countertransference With Borderline Patients. Washington, DC, American Psychiatric Press, 1994
 
Gabbard GO, Horwitz L, Allen JG, et al: Transference interpretation in the psychotherapy of borderline patients: a high-risk, high-gain phenomenon. Harv Rev Psychiatry 2:56–69, 1994
 
Gardner DL, Cowdry RW: Alprazolam-induced dyscontrol in borderline personality disorder. Am J Psychiatry 142:98–100, 1985
[PubMed]
 
Gardner DL, Cowdry RW: Positive effects of carbamazepine on behavioral dyscontrol in borderline personality disorder. Am J Psychiatry 143:519–522, 1986
[PubMed]
 
Goldberg S, Shulz S, Shulz P: Borderline and schizotypal personality disorders treated with low-dose thiothixene versus placebo. Arch Gen Psychiatry 43:680–690, 1986
[PubMed]
 
Gratz KL, Gunderson JG: Preliminary data on an acceptance-based emotion regulation group intervention for deliberate self-harm among women with borderline personality disorder. Behav Ther 37:25–35, 2006
[PubMed]
 
Gunderson JG: Borderline Personality Disorder. Washington, DC, American Psychiatric Press, 1984
 
Gunderson JG: Borderline Personality Disorder: A Clinical Guide. Washington, DC, American Psychiatric Publishing, 2001
 
Gunderson JG, Hoffman PD: Understanding and Treating Borderline Personality Disorder: A Guide for Professionals and Families. Washington, DC, American Psychiatric Publishing, 2005
 
Gunderson JG, Kerr J, Englund DW: The families of borderlines: a comparative study. Arch Gen Psychiatry 37:27–33, 1980
[PubMed]
 
Gunderson JG, Frank AF, Ronningstam EF, et al: Early discontinuance of borderline patients from psychotherapy. J Nerv Ment Dis 177:38–42, 1989
[PubMed]
 
Gunderson JG, Berkowitz C, Ruiz-Sancho A: Families of borderline patients: a psychoeducational approach. Bull Menninger Clin 61:446–457, 1997
[PubMed]
 
Gunderson JG, Morey LC, Stout RL, et al: Major depressive disorder and borderline personality disorder revisited: longitudinal interactions. J Clin Psychiatry 65:1049–1056, 2004
[PubMed]
 
Gunderson JG, Daversa MT, McGlashan TH, et al: Predictors of 2-year outcome for patients with borderline personality disorder. Am J Psychiatry 163:822–826, 2006
[PubMed]
 
Guyatt G, Sackett D, Adachi J, et al: A clinician's guide for conducting randomized trials in individual patients. Can Med Assoc J 139:497–503, 1988
[PubMed]
 
Hoch P, Polatin P: Pseudoneurotic forms of schizophrenia. Psychiatr Q 23:248–276, 1949
 
Hoffman PD, Buteau E, Hooley JM, et al: Family members' knowledge about borderline personality disorder: correspondence with their levels of depression, burden, distress and expressed emotion. Fam Process 42:469–478, 2003
[PubMed]
 
Hoge MA, Davidson L, Hill WL, et al: The promise of partial hospitalization: a reassessment. Hosp Community Psychiatry 43:345–354, 1992
[PubMed]
 
Hoke L: Longitudinal patterns of behaviors in borderline personality disorder. Unpublished dissertation, Boston University Graduate School, Boston, MA, 1989
 
Hollander E: Managing aggressive behavior in patients with obsessive-compulsive disorder and borderline personality disorder. J Clin Psychiatry 60 (suppl):38–44, 1999
 
Hollander E, Tracy KA, Swann AC, et al: Divalproex in the treatment of impulsive aggression: efficacy in Cluster B personality disorders. Neuropsychopharmacology 28:1186–1197, 2003
[PubMed]
 
Hollander E, Swann AC, Coccaro E, et al: Impact of trait impulsivity and state aggression on divalproex versus placebo response in borderline personality disorder. Am J Psychiatry 162:621–624, 2005
[PubMed]
 
Hooley JM, Hoffman PD: Expressed emotion and clinical outcome in borderline personality disorder. Am J Psychiatry 156:1557–1562, 1999
[PubMed]
 
Howard KI, Kopta SM, Krause MS, et al: The dose-effect relationship in psychotherapy. Am Psychol 41:159–164, 1986
[PubMed]
 
Kernberg OF: The treatment of patients with borderline personality organization. Int J Psychoanal 49:600–619, 1968
[PubMed]
 
Kernberg OF: Borderline Conditions and Pathological Narcissism. New York, Jason Aronson, 1975
 
Kernberg OF, Coyne L, Horwitz L, et al: Psychotherapy and psychoanalysis. The application of facet theory and the multidimensional scalogram analysis to the quantitative data of the psychotherapy research project. Bull Menninger Clin 36:87–275, 1972
[PubMed]
 
Kernberg OF, Selzer MA, Koenigsberg HW, et al: Psychodynamic Psychotherapy of Borderline Patients. New York, Basic Books, 1989
 
Khouzam HR, Donnelly NJ: Remission of self-mutilation in a patient with borderline personality during risperidone therapy. J Nerv Ment Dis 195:348–349, 1997
 
Knight R: Borderline states. Bull Menninger Clin 17:1–12, 1953
[PubMed]
 
Kohut H: The Analysis of the Self. New York, International Universities Press, 1971
 
Leone NF: Response of borderline patients to loxapine and chlorpromazine. J Clin Psychiatry 43:148–150, 1982
[PubMed]
 
Linehan MM: Cognitive-Behavioral Treatment of Borderline Personality Disorder. New York, Guilford, 1993a
 
Linehan MM: Skills Training Manual for Treating Borderline Personality Disorder. New York, Guilford, 1993b
 
Links PS: Psychiatric rehabilitation model for borderline personality disorder. Can J Psychiatry 38:535–538, 1993
 
Links PS: Developing effective services for patients with personality disorders. Can J Psychiatry 43:251–259, 1998
[PubMed]
 
Links PS, Stockwell M: Is couple therapy indicated for borderline personality disorder? Am J Psychother 55:491–506, 2001
[PubMed]
 
Links PS, Steiner M, Boiago I, et al: Lithium therapy for borderline patients: preliminary findings. J Personal Disord 4:173–181, 1990
 
Links PS, Heslegrave RJ, Mitton JE, et al: Borderline personality disorder and substance abuse: consequences of comorbidity. Can J Psychiatry 40:9–14, 1995a
 
Links PS, Heslegrave RJ, Mitton JE, et al: Borderline psychopathology and recurrences of clinical disorders. J Nerv Ment Dis 183:582–586, 1995b
 
Links PS, Heslegrave R, Villella J: Psychopharmacological management of personality disorders: an outcome focused model, in Biology of Personality Disorders. Edited by Silk KR. Washington, DC, American Psychiatric Press, 1998, pp 93–127
 
Livesley WJ: Practical Management of Personality Disorder. New York, Guilford, 2003
 
Maltsberger JT, Buie DH: Countertransference hate in the treatment of suicidal patients. Arch Gen Psychiatry 30:625–633, 1974
[PubMed]
 
Markovitz PJ, Wagner SC: Venlafaxine in the treatment of borderline personality disorder. Psychopharmacol Bull 31:773–777, 1995
[PubMed]
 
Marziali E, Munroe-Blum H: Interpersonal Group Psychotherapy for Borderline Personality Disorder. New York, Basic Books, 1994
 
Montgomery SA: The psychopharmacology of borderline personality disorder. Acta Psychiatr Belg 87:260–266, 1987
[PubMed]
 
Montgomery SA, Montgomery D: Pharmacological prevention of suicidal behavior. J Affect Disord 4:291–298, 1982
[PubMed]
 
Nemeroff DB: The role of GABA in the pathophysiology and treatment of anxiety disorders. Psychopharmacol Bull 37:133–146, 2003
[PubMed]
 
Paris J: Commentary of the American Psychiatric Association guidelines for the treatment of borderline personality disorder: evidence-based psychiatry and the quality of evidence. J Personal Disord 16:130–134, 2002
[PubMed]
 
Parsons B, Quitkin FM, McGrath PJ, et al: Phenelzine, imipramine, and placebo in borderline patients meeting criteria for atypical depression. Psychopharmacol Bull 25:524–534, 1989
[PubMed]
 
Philipsen A, Schmahl C, Lieb K: Naloxone in the treatment of acute dissociative states in female patients with borderline personality disorder. Pharmacopsychiatry 37:196–199, 2004
[PubMed]
 
Pinto OC, Akiskal HS: Lamotrigine as a promising approach to borderline personality: an open case series without concurrent DSM-IV major mood disorder. J Affect Disord 51:333–343, 1998
[PubMed]
 
Rinne T, van den Brink W, Wouters L, et al: SSRI treatment of borderline personality disorder: a randomized, placebo-controlled clinical trial for female patients with borderline personality disorder. Am J Psychiatry 159:2048–2054, 2002
[PubMed]
 
Robins CJ, Chapman AL: Dialectical behavior therapy: current status, recent developments, and future directions. J Personal Disord 18:73–89, 2004
[PubMed]
 
Rockland LH: Supportive Therapy for Borderline Patients: A Psychodynamic Approach. New York, Guilford, 1992
 
Rothstein MM, Vallis TM: Application of cognitive therapy to patients with personality disorders, in The Challenge of Cognitive Therapy: Applications to Nontraditional Populations. Edited by Vallis TM, Howes JL, Miller PC. New York, Plenum, 1992, pp 59–84
 
Rutter D, Tyrer P: The value of therapeutic communities in the treatment of personality disorders: a suitable place for treatment? J Psychiatr Pract 9:291–302, 2003
[PubMed]
 
Ryle A: The contribution of cognitive analytic therapy to the treatment of borderline personality disorder. J Personal Disord 18:3–35, 2004
[PubMed]
 
Schmahl C, Stiglmayr C, Bohme R, et al: Treatment of dissociative symptoms in borderline patients with naltrexone [in German]. Nervenarzt 70:262–264, 1999
[PubMed]
 
Schulz SC, Camlin KL, Berry SA, et al: Olanzapine safety and efficacy in patients with borderline personality disorder and comorbid dysthymia. Biol Psychiatry 46:1429–1435, 1999
[PubMed]
 
Serban G, Siegel S: Response of borderline and schizotypal patients to small doses of thiothixene and haloperidol. Am J Psychiatry 141:1455–1458, 1984
[PubMed]
 
Shapiro ER, Zinner J, Shapiro R, et al: The influence of family experience on borderline personality development. Int Rev Psychoanal 2:399–411, 1975
 
Siever LJ, Klar H, Coccaro E: Psychological substrates of personality, in Biological Response Styles: Clinical Implications. Edited by Klar H, Siever LJ. Washington, DC, American Psychiatric Press, 1985, pp 35–66
 
Silk KR, Eisner W, Demars C, et al: Interrupted inpatient treatment of borderlines. Paper presented at the annual meeting of the American Psychiatric Association, Washington, DC, May 1992
 
Silver D: Psychotherapy of the characterologically difficult patient. Can J Psychiatry 28:513–521, 1983
[PubMed]
 
Silver D: Psychodynamics and psychotherapeutic management of the self-destructive character-disordered patient. Psychiatr Clin North Am 8:357–375, 1985
[PubMed]
 
Silver D, Rosenbluth M: Inpatient treatment of borderline personality disorder, in Borderline Personality Disorder: Etiology and Treatment. Edited by Paris J. Washington, DC, American Psychiatric Press, 1993, pp 349–372
 
Skodol AE, Buckley P, Charles E: Is there a characteristic pattern to the treatment history of clinical outpatients with borderline personality? J Nerv Ment Dis 171:405–410, 1983
[PubMed]
 
Soloff PH: What's new in personality disorders? An update on pharmacological treatment. J Personal Disord 4:233–243, 1990
 
Soloff PH: Pharmacological therapies in borderline personality disorder, in Borderline Personality Disorder: Etiology and Treatment. Edited by Paris J. Washington, DC, American Psychiatric Press, 1993, pp 319–348
 
Soloff PH: Algorithm for pharmacological treatment of personality dimensions: symptom-specific treatments for cognitive-perceptual, affective and impulsive-behavioral dysregulation. Bull Menninger Clin 62:195–214, 1998
[PubMed]
 
Soloff PH: Psychopharmacology of borderline personality disorder. Psychiatr Clin North Am 23:169–192, 2000
[PubMed]
 
Soloff PH, George A, Nathan RS, et al: Progress in pharmacotherapy of borderline disorders: a double-blind study of amitriptyline, haloperidol, and placebo. Arch Gen Psychiatry 43:691–697, 1986
[PubMed]
 
Soloff PH, Cornelius J, George A, et al: Efficacy of phenelzine and haloperidol in borderline personality disorder. Arch Gen Psychiatry 50:377–385, 1993
[PubMed]
 
Stein DJ, Simeon D, Frenkel M, et al: An open trial of valproate in borderline personality. J Clin Psychiatry 56:506–510, 1995
[PubMed]
 
Stevenson J, Meares R: An outcome study of psychotherapy for patients with borderline personality disorder. Am J Psychiatry 149:358–362, 1992
[PubMed]
 
Szigethy EM, Schulz SC: Risperidone in comorbid borderline personality and dysthymia. J Clin Psychopharmacol 17:326–327, 1997
[PubMed]
 
Tyrer P, Davidson K: Cognitive therapy of personality disorders, in Psychotherapy for Personality Disorders (Review of Psychiatry Series, Vol 19, No 3; Oldham JO and Riba MB, series eds). Edited by Gunderson JG, Gabbard GO. Washington, DC, American Psychiatric Press, 2000, pp 131–149
 
Tyrer P, Simmonds S: Treatment models for those with severe mental illness and comorbid personality disorder. Br J Psychiatry 182 (suppl):S15–S18, 2003
 
Tyrer P, Thompson S, Schmidt U, et al: Randomized controlled trial of brief cognitive behaviour therapy versus treatment as usual in recurrent deliberate self-harm: the POPMACT study. Psychol Med 33:969–976, 2003
[PubMed]
 
Volkan V: Six Steps in the Treatment of Borderline Personality Organization. New York, Jason Aronson, 1987
 
Waldinger R, Gunderson JG: Effective Psychotherapy With Borderline Patients. New York, Macmillan, 1987
 
Wallerstein R: Forty-Two Lives in Treatment: A Study of Psychoanalysis and Psychotherapy. New York, Guilford, 1986
 
Weinberg I, Gunderson JG, Hennen J, et al: Manual assisted cognitive treatment for deliberate self-harm in borderline personality disorder patients. J Personal Disord 20:482–492, 2006
[PubMed]
 
Widiger TA, Frances A: Epidemiology, diagnosis, and comorbidity of borderline personality disorder, in American Psychiatric Press Review of Psychiatry, Vol 8. Edited by Tasman A, Hales RE, Frances AJ. Washington, DC, American Psychiatric Press, 1989, pp 8–24
 
Winnicott DW: Hate in the countertransference (1947), in Collected Papers. New York, Basic Books, 1975, pp 194–203
 
Yen S, Shea MT, Sanislow CA, et al: Borderline personality disorder criteria associated with prospectively observed suicidal behavior. Am J Psychiatry 161:1296–1298, 2004
[PubMed]
 
Yeomans FE, Selzer M, Clarkin J: Studying the treatment contract in intensive psychotherapy with borderline patients. Psychiatry 56:254–263, 1993
[PubMed]
 
Young JE, Klosko JS, Weishaar ME: Schema Therapy: A Practitioner's Guide. New York, Guilford, 2003
 
Zanarini MC, Frankenberg FR: Olanzapine treatment of female borderline personality disorder patients: a double-blind placebo-controlled trial. J Clin Psychiatry 62:849–854, 2001
[PubMed]
 
Zanarini MC, Frankenburg FR, Dubo ED, et al: Axis I comorbidity of borderline personality disorder. Am J Psychiatry 155:1733–1739, 1998
[PubMed]
 
Zanarini MC, Frankenburg FR, Hennen J, et al: Axis I comorbidity in patients with borderline personality disorder: 6-year follow-up and prediction of time to remission. Am J Psychiatry 161:2108–2114, 2004a
 
Zanarini MC, Frankenberg FR, Hennen J, et al: Mental health service utilization by borderline personality disorder patients and Axis II comparison subjects followed prospective for 6 years. J Clin Psychiatry 65:28–36, 2004b
 
Zanarini MC, Frankenberg FR, Parachini EA: A preliminary randomized trial of fluoxetine, olanzapine and the olanzapine-fluoxetine combination in women with borderline personality disorder. J Clin Psychiatry 65:903–907, 2004c
 
Zimmerman M, Coryell W, Pfohl B: ECT response in depressed patients with and without a DSM-III personality disorder. Am J Psychiatry 143:1030–1032, 1986
[PubMed]
 
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Related Content
Articles
Books
Topic Collections
Psychiatric News
PubMed Articles
 
  • Print
  • PDF
  • E-mail
  • Chapter Alerts
  • Get Citation